Patient, Elizabeth Acuna, describes some of the medications she has been on, and currently is taking, to treat her atopic dermatitis, and their effect on her quality of life.
Views: 3495 AJMCtv
Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, says the buy-and-bill model is most typically applied to the provider space, and more specifically to physicians' offices. It describes the supply chain for infusion medications, predominately self-injectables that require clinical monitoring, and that are administered or sourced through practitioners. In this model, buying refers to the procurement of the drugs by the practice, and the billing refers to the bill sent directly to payers. "There's been a growth in the number of hospital outpatient centers that source drugs and then bill payers directly through their contracts," says Dr Singh; "And that's on the rise given the acquisitions of physician practices in oncology and in other relevant specialties."
Views: 1957 AJMCtv
In this segment, Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, discuss sodium-glucose co-transporter 2 inhibition in patients with diabetes and corresponding outcomes on cardiovascular events.
Views: 1425 AJMCtv
There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.
Views: 1575 AJMCtv
During the opening segment of this program, part of the Healthcare Reform Stakeholders Summit, Spring 2015 series, moderator Dennis Patrick Scanlon, PhD, asks managed care stakeholders Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, for their insights on the goals of value-based purchasing programs and the roles of various stakeholders in these programs.
Views: 2276 AJMCtv
Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.
Views: 685 AJMCtv
The new ADHD drug for adults, Mydayis, works with multiple beads being released at different times of the day so patients are only taking one medication that lasts for up to 16 hours instead of multiple dosings throughout the day, explained Manisha Madhoo, MD, vice president of Global Medical Affairs, Neuroscience, Shire.
Views: 2681 AJMCtv
Expert John Anderson, MD, reviews the cardiovascular outcomes data available to date with GLP-1 receptor agonists in type 2 diabetes.
Views: 477 AJMCtv
The accountable care organization (ACO) programs—the Pioneer, Shared Savings, and Next Generation models—and how they relate to provider risk is addressed by panel members Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, during this 12th session of the Healthcare Reform Stakeholder Summit. Risk factors for various models are also discussed.
Views: 1889 AJMCtv
John B. Buse, MD, PhD, offers his perspective on the LEADER trial with liraglutide and the potential reasons for the cardiovascular effects in patients with type 2 diabetes.
Views: 535 AJMCtv
Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness.
Views: 571 AJMCtv
Amrita Krishnan, MD, FACP, elucidates various combination treatment approaches making use of daratumumab in the frontline setting for patients with newly diagnosed multiple myeloma.
Views: 342 AJMCtv
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH. This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Views: 1821 AJMCtv
Rick Doubleday, the executive vice president and chief commercial officer at Dexcom, discusses his company's new partnership with Fitbit and what patients with both type 1 and type 2 diabetes will get out of it.
Views: 647 AJMCtv
In the search for a safe and effective treatment for atopic dermatitis (AD), new research looks at the immune pathway of psoriasis to potentially help target AD, according to Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
Views: 1052 AJMCtv
Zachary T. Bloomgarden, MD, MACE, describes the treatment options available for the management of diabetes and remarks on the differences between the clinical guidelines that have been released to assist healthcare providers in managing patients with diabetes.
Views: 1386 AJMCtv
Tina Joseph, PharmD, BCACP, assistant professor, college of pharmacy, Nova Southeastern University, discusses collaborative practice agreements between pharmacists and physicians as well as the challenges with and best practices for successful implementation.
Views: 345 AJMCtv
Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs outlined the purpose of a study on real-world results of comparing basal insulin dose changes in type 2 diabetes patients using Lantus who either stay on Lantus or switch to Toujeo.
Views: 524 AJMCtv
Steven Coutre, MD, highlights the latest drug approval of ibrutinib for frontline therapy in patients with chronic lymphocytic leukemia and its role in long-term treatment.
Views: 1387 AJMCtv
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
Views: 973 AJMCtv
Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. Panelists were Andrea Baer, MS, of Mended Hearts, Inc; Jalpa A. Doshi, PhD, of University of Pennsylvania; Mary Richards of Partners for Better Care; Veena Shankaran, MD, MS, of University of Washington and Fred Hutchinson Cancer Research Center; and Kai Yeung, PharmD, PhD, of Group Health Research Institute. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care.
Views: 3339 AJMCtv
The use of on-demand data in the healthcare setting has gone through an evolution, where the beginning steps were about pulling information into 1 pool and then understanding how to analyze it. According to Lidia Fonseca, senior vice president and chief information officer of Quest Diagnostics, the next step in this process is integrating this technology into the workflow of physicians and using the information in a real time and impactful way.
Views: 578 AJMCtv
During this segment, Patrick F. Fogarty, MD, discusses the treatment goals for hemophilia, based on disease severity. Dr Fogarty defines prophylaxis, explains primary and secondary prophylaxis for the treatment of mild and severe hemophilia, and discusses the recommended target trough levels and dosage requirements based on disease severity. He continues by discussing how treatment expectations are similar between patients, their family members, and providers. From a pediatric standpoint, Dr Fogarty stresses the importance of providing patients the best opportunity for a normal lifestyle, and explains that as longer-acting proteins continue to develop, there is an opportunity to administer intravenous therapy less frequently. Dr Fogarty concludes by briefly discussing the benefits of the agents that are currently available to treat patients with mild and severe hemophilia, and cites a recent study that treated patients with a regimen of recombinant clotting factor 8 concentrate and revealed positive results on patients' quality of life.
Views: 298 AJMCtv
Diabetes is an insidious cardiometabolic condition that continues to affect a growing population of young Americans, and is associated with high blood pressure, lipid abnormalities, and renal disease. The disease and its clinical sequelae are tightly interwoven with cardiovascular disease (CVD), acute coronary syndrome, and stroke. Consequently, there are substantial clinical implications for the optimal management of any underlying cardiometabolic disorder. While the topic of "metabolic syndrome" remains controversial and inconsistently defined, Dr Michael Weber emphasizes that glycosylated hemoglobin A1c (HbA1c), while the standard measure for the management of diabetes, is only one component of the overall picture - it is also essential to appropriately control body weight and size, blood pressure, and lipid levels.
Views: 117 AJMCtv
Farzad Mostashari, MD, co-founder and CEO of Aledade and former National Coordinator of Health Information Technology, discusses the benefits of Aledade’s technology, combined with its strategies and analytics, and how these tools are implemented among the practices with which Aledade is working.
Views: 375 AJMCtv
In this segment, Christopher Sweeney, MBBS, discusses the results of the ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED). Dr Sweeney also discusses how the results of CHAARTED have impacted the treatment of patients with prostate cancer and influenced research on combination therapy.
Views: 335 AJMCtv
Panelists Peter L. Salgo, MD; Charles Wykoff, MD, PhD; and Jared Nielsen, MD, describe the mechanism of action and role of anti-VEGF therapies in the treatment of wet age-related macular degeneration.
Views: 312 AJMCtv
John B. Buse, MD, PhD, reviews the findings from the ELIXA trial with lixisenatide in patients with type 2 diabetes.
Views: 319 AJMCtv
Despite the potential benefits of sharing healthcare data, Rena M. Conti, PhD; Brenton Fargnoli, MD; and Andrew L. Pecora, MD, CPE; note that there are also several associated challenges. The panelists suggest that engaging patients to be responsible for their electronic health records can improve care.
Views: 337 AJMCtv
The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.
Views: 368 AJMCtv
Dennis P. Scanlon, PhD; Zachary T. Bloomgarden, MD, MACE; Robert Gabbay, MD, PhD, FACP; Michael Gardner, MD; and John A. Johnson, MD, MBA; discuss the results of recent clinical trials that evaluated cardiovascular outcomes associated with various diabetes treatments when used as add-on therapy.
Views: 2216 AJMCtv
Steven Coutre, MD, discusses the various factors that influence treatment decisions in chronic lymphocytic leukemia and the potential for more individualized approaches.
Views: 478 AJMCtv
Dr. Tobias Loddenkemper, MD, the Assistant Professor in Neurology at Harvard Medical School, discusses the challenges and goals associated with the treatment of refractory status epilepticus (SE) in the pediatric populations, especially noting the cognitive and developmental considerations. This video was taken on Friday, November 30th at the American Epilepsy Society's 2012 Annual Meeting in San Diego, CA.
Views: 802 AJMCtv